Kanvas Biosciences (@kanvas), where I'm Chair, has been greenlit to begin trials for its first drug, KAN-004, targeting ICI-induced colitis. KAN-001, a potential blockbuster, that treats ICI-naive and -refractory cancers, to begin later this year.
Remarkable progress for a company founded in 2020 that only began its clinical programs a few years ago. Many congratulations to CEO Matt Cheng, CTO Hao Shi, and Chief Development Officer Lee Swem, and the whole Kanvas team.

Twitter

Source: Synced

Just now, a historic "closed-door" event occurred in the AI community.

Anthropic has officially banned access to OpenClaw using its own subscription plan!!!

Boris Cherny, the creator of Claude Code, announced: Starting at 3 PM EST on April 4th (3 AM Beijing time on April 5th), Claude will block all third-party tools; access to these tools will only be available through additional subscription plans or APIs.

[OpenClaw] This means that thousands of users who rely on OpenClaw for improvements...

Anthropic officially blocks OpenClaw, causing a global developer crisis within 24 hours.

MicroStrategy founder Michael Saylor asserts that Bitcoin has won the global narrative war, specifically naming BIP- […]
The article, "Michael Saylor Warns BIP-110 is the Biggest Threat to Bitcoin; Four-Year Cycle is Dead, Institutional Capital is the Real Protagonist," was first published on BlockTempo, the most influential blockchain ABMedia media.

Michael Saylor warns that BIP-110 is the biggest threat to Bitcoin; the four-year cycle is dead, and institutional capital is the real protagonist.

Warnings of a looming economic rupture are intensifying as Robert Kiyosaki links inflation, oil shocks, and retirement strain to decades-old policy shifts that may now be converging in 2026.
Key Takea...